489TiP BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)

H Liu,P Zhang,B Wei,J He,W Liang,W Zheng,J Shi,W Yu,N Wu,Z Shen

doi:10.1016/j.annonc.2023.10.563

489TiP BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)

H Liu, P Zhang + Show 8 more

https://doi.org/10.1016/j.annonc.2023.10.563

Copy DOI

Journal: Annals of Oncology

Publication Date: Nov 1, 2023

Affiliation: Liaoning Cancer Hospital & Institute, Shanghai Pulmonary Hospital, First Affiliated Hospital of Guangzhou Medical University, BeiGene (China), Peking University Cancer Hospital

#IIIA Non-small Cell Lung Cancer #Treatment In Chinese Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

489TiP BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)

Full Text